Heart Conditions — Expert Guides

Does a Coffee a Day Keep AF at Bay?

April 22, 2026

Key Points

A new clinical trial published in JAMA found that patients with atrial fibrillation who continued drinking around one cup of coffee a day were 39% less likely to have a recurrence of AF compared to those who stopped completely.
This is the first randomised clinical trial to directly test whether coffee triggers AF episodes, overturning decades of routine clinical advice to avoid caffeine.
The finding does not mean patients should increase their coffee intake, and it does not apply to everyone. The trial involved patients who were already moderate coffee drinkers.
As with all research, there are limitations, and guidelines have not yet changed. Talk to your cardiologist before changing anything about your daily habits.

If you have been told you have atrial fibrillation, there is a good chance someone, whether a doctor, a nurse, or a well-meaning friend, has suggested you cut back on coffee. For years, caffeine has been viewed with suspicion in the context of heart rhythm disorders, and many patients with AF have quietly given up their morning cup out of caution. If you experience palpitations or an irregular heartbeat and are not sure whether it is related to AF, our dedicated article on palpitations explains what different sensations mean and when to seek help.

A major new clinical trial, published in JAMA in 2026 and conducted across five hospitals in Australia, the United States, and Canada, has now challenged that longstanding advice in a way that will be meaningful for many people living with AF.

The short version: in patients who already drank moderate amounts of coffee, continuing to drink around one cup a day after cardioversion was not harmful, and may actually have been protective against the return of irregular heart rhythm.

What is the DECAF trial?

DECAF stands for Does Eliminating Coffee Avoid Fibrillation, which neatly captures the question the researchers set out to answer. It is the first randomised clinical trial ever conducted on this specific question, which makes it a landmark study even by the standards of cardiology research.

The trial enrolled 200 adults with persistent AF who were all scheduled for cardioversion, the procedure that uses a controlled electrical impulse to reset the heart back into a normal rhythm. The average age of participants was 69 years and 71% were male. All were moderate coffee drinkers, consuming around seven cups per week, which is roughly one cup a day, at some point in the previous five years.

After successful cardioversion, patients were randomly assigned to one of two groups. One group was asked to continue drinking at least one cup of caffeinated coffee each day. The other group was asked to avoid all coffee and caffeine entirely, including decaffeinated coffee. Most participants were already being treated for AF with anticoagulation and some with antiarrhythmic or rate control medications, and these were continued throughout the trial. Both groups were then followed for six months to see whose heart rhythm stayed normal and whose returned to AF. The coffee group maintained their habit of around seven cups per week throughout the trial, while the abstinence group reduced to essentially none.

☕ Coffee group

47% of patients who continued drinking coffee had a recurrence of AF or atrial flutter within six months.

🚫 No coffee group

64% of patients who avoided all caffeine had a recurrence of AF or atrial flutter within six months.

📉 The difference

Patients who continued drinking coffee were 39% less likely to have a recurrence of AF compared to those who abstained entirely.

✅ Safety

Emergency visits and hospitalisations were similar between both groups. No deaths occurred in either group during the trial.

☕ What does this mean in practice?

For every 6 people with AF who continued drinking their daily coffee after cardioversion, approximately 1 avoided a recurrence that they would otherwise have had. That is a meaningful real-world benefit, and a number worth discussing with your cardiologist.

The result was statistically significant, meaning it is unlikely to be explained by chance alone. The lead investigator, Professor Christopher Wong of the University of Adelaide, described the results as astounding, noting that the trial suggests coffee is not only safe but potentially protective for patients with AF. Importantly, the DECAF trial was funded by the National Institutes of Health, with no pharmaceutical or industry sponsorship involved, which strengthens confidence in the independence of the findings.

Why might coffee help rather than hurt?

For decades, the assumption was that caffeine, as a stimulant, would make the heart more prone to irregular rhythms. The DECAF trial suggests the reality is more nuanced. The researchers and commentators offered several possible explanations for why moderate coffee consumption might actually be associated with fewer AF episodes.

Adenosine blockade

Caffeine blocks adenosine receptors in the heart. Adenosine can promote the conditions that allow AF to develop and persist, so blocking it may have a protective effect.

Anti-inflammatory effects

Coffee contains compounds beyond caffeine that have anti-inflammatory properties. Inflammation plays a role in the development of AF, so reducing it may help maintain normal rhythm.

Physical activity

Coffee is associated with increased physical activity, and exercise is known to reduce AF burden. Patients in the coffee group may have been more active as a result.

Caffeine withdrawal

Abruptly stopping caffeine causes physiological changes that may themselves be disruptive to heart rhythm. Regular moderate consumption avoids this stress on the body.

What are the limitations of this trial?

No single clinical trial, however well-designed, changes medical practice on its own, and the DECAF researchers themselves were careful to highlight several important limitations that patients should understand.

The trial enrolled 200 patients, which is a relatively modest number in the world of clinical cardiology. While the result was statistically significant, a larger study could either strengthen or modify these findings. The open-label design, meaning that both patients and researchers knew which group each person was in, could also influence how symptoms were reported or how often patients sought medical attention. There were also some differences in baseline characteristics between the two groups: the abstinence group was on average two years older and included more women, which may have influenced the results despite statistical adjustments.

The researchers also noted that AF episodes were detected through routine clinical care rather than a standardised monitoring schedule, which means some episodes in either group may not have been captured.

For years I have had the conversation in clinic about coffee and AF. Most patients ask about it, and until now the honest answer was that we did not have good randomised evidence either way. The DECAF trial changes that. For patients who are already moderate coffee drinkers, this is genuinely reassuring. But it is not a signal to start drinking more, and it is not a study of patients who never drank coffee. Context matters, and the conversation with your cardiologist still matters.

What does this mean for you?

If you have AF and you have been worried about your morning coffee, this trial offers genuine reassurance. For patients who are already moderate coffee drinkers, the best available evidence now suggests that continuing to drink around one cup a day is not harmful and may, if anything, be beneficial for heart rhythm stability after cardioversion.

However, it is important to understand what this trial does not tell us. It was not conducted in people who do not drink coffee at all, so it does not suggest that non-coffee-drinkers should start. It does not apply to large amounts of caffeine. It does not mean that every patient with AF should drink more coffee. And it does not override the advice of your own cardiologist, who knows your specific heart anatomy, medications, and circumstances.

Clinical guidelines have not yet been updated to reflect this trial, and further research will follow. In the meantime, the most sensible message is that you no longer need to feel guilty about your morning cup, but as always, any significant changes to your lifestyle or habits are worth discussing with your clinical team first.

Conclusion

The DECAF trial is a genuinely important piece of research that challenges a longstanding assumption in cardiology. For decades, patients with AF have been advised, often without strong evidence, to avoid caffeine. The first properly conducted randomised trial on this question tells a different story: for moderate coffee drinkers, continuing to enjoy one cup a day after cardioversion appears to be safe and may reduce the likelihood of AF returning.

It is a finding worth knowing about. It is also a reminder that in medicine, advice that has been repeated for many years is not always grounded in the evidence we now have the tools to generate. This trial gave us that evidence, and it is genuinely good news for the many patients with AF who have been quietly missing their coffee.

References

Wong CX, Cheung CC, Montenegro G, et al. Caffeinated Coffee Consumption or Abstinence to Reduce Atrial Fibrillation: The DECAF Randomized Clinical Trial. JAMA. 2026;335(4):317-325. doi:10.1001/jama.2025.21056
First presented by Christopher X. Wong, MBBS, MPH, PhD, at the American Heart Association Scientific Sessions 2025, New Orleans, LA, November 9, 2025. Published in print JAMA January 27, 2026
Funding: The DECAF trial was supported by the National Institutes of Health (NIH), National Heart, Lung and Blood Institute. No commercial or industry funding was involved in this research.

Iron Deficiency and the Heart

April 18, 2026April 14, 2026

Key Points

Iron deficiency is extremely common in cardiac patients, particularly those with heart failure, chronic kidney disease, or those taking blood-thinning medications long-term.
You do not need to be anaemic to be iron deficient. Many patients have low iron stores with a normal haemoglobin, and still experience significant fatigue and reduced exercise capacity.
Medications including aspirin, dual antiplatelet therapy, and anticoagulants (blood thinners) can cause low-grade, ongoing gastrointestinal blood loss that slowly depletes iron stores over months to years.
In heart failure, correcting iron deficiency, even without anaemia, significantly improves symptoms, exercise capacity, and quality of life, and reduces hospital admissions.
When oral iron supplements are poorly tolerated or inadequately absorbed, intravenous iron infusion is safe, effective, and increasingly available.
Iron levels are straightforward to check with a blood test. If you are experiencing unexplained fatigue and are on cardiac medications, asking your doctor about iron studies is worthwhile.

Iron deficiency and the heart have a closer connection than most people realise. It sits in the background of the cardiovascular conversation, overshadowed by cholesterol, blood pressure, and rhythm, and yet it is one of the most prevalent and most correctable problems in cardiac patients.

In cardiology and haematology clinics, iron deficiency turns up regularly. In patients on long-term blood thinners, in those managing heart failure, in people with chronic kidney disease. Recognising it, testing for it, and treating it effectively can make a profound difference to how a patient feels and functions day to day.

Iron Deficiency and the Heart, Why Are Cardiac Patients at Risk?

Several factors make cardiac patients particularly vulnerable to iron depletion. Understanding them helps explain why this problem is so common in this specific group.

Blood-Thinning Medications and Slow Blood Loss

Many cardiac patients take medications that reduce the blood’s ability to clot, aspirin, dual antiplatelet therapy (aspirin combined with clopidogrel or ticagrelor), or anticoagulants such as warfarin or DOACs (direct oral anticoagulants). These medications are essential and life-saving in the right context.

But they carry a side effect that is easy to overlook: low-grade, ongoing blood loss from the gastrointestinal tract. The gut lining is naturally prone to minor bleeding, small erosions and microscopic leaks that the body usually handles without consequence.

When platelet function is reduced or clotting is impaired, these tiny bleeds become slightly larger and slightly more persistent. Over months and years, the cumulative blood loss is enough to steadily deplete iron stores, even without any obvious sign of bleeding.

I see this regularly, a patient on long-term blood thinners who has been increasingly fatigued for months. Their haemoglobin is normal, so anaemia has been excluded. But their ferritin is very low and their iron stores are essentially empty. Correcting it changes everything.

— A/Prof. Ali Bazargan, Haematologist

Medication	How It Can Deplete Iron	Risk Level
Aspirin	Reduces the blood’s clotting ability and can irritate the stomach lining, leading to minor ongoing blood loss	Moderate, increases with dose and duration
Dual antiplatelet therapy	Two clot-preventing medicines combined, greater stomach and gut bleeding risk than aspirin alone	Higher, particularly in first 12 months
Warfarin	Reduces the blood’s ability to clot, any gut bleed is larger and slower to stop	Moderate to high, especially when the blood-thinning effect is stronger than intended
DOACs (apixaban, rivaroxaban, dabigatran)	Direct blood thinners, gut bleeding risk varies by medication and dose	Moderate, rivaroxaban carries slightly higher gut bleeding risk than apixaban

Heart Failure

Iron deficiency is extraordinarily common in heart failure, affecting up to 50% of patients with the condition. The reasons are multiple: reduced appetite, gut wall swelling that impairs iron absorption, and chronic low-grade inflammation that prevents iron from being properly used.

In some patients, underlying kidney disease compounds the problem further.

What makes this particularly important is that iron deficiency worsens heart failure outcomes independently of whether anaemia is present. The heart muscle itself requires iron for energy production. Iron-deficient cardiac muscle functions less efficiently, contributing directly to the breathlessness, fatigue, and exercise intolerance that define heart failure symptoms.

50%
of patients with heart failure have iron deficiency, one of the most common and most treatable problems in this group, with or without anaemia
European Heart Journal

Chronic Kidney Disease

The kidneys play a central role in iron metabolism. They produce a hormone called erythropoietin, a chemical signal that tells the bone marrow to produce red blood cells, a process that requires iron. In chronic kidney disease, this signalling is impaired and iron utilisation breaks down.

Patients with chronic kidney disease are therefore at high risk of iron deficiency through multiple mechanisms simultaneously, reduced production, impaired utilisation, and often dietary restrictions or gut absorption problems on top.

Iron deficiency in this setting is a major driver of fatigue and anaemia, and managing it is an important part of comprehensive kidney and cardiac care.

Iron Deficiency Without Anaemia, Why This Matters

One of the most important things to understand is that iron deficiency and anaemia are not the same thing. Anaemia, a low haemoglobin or red cell count, is the late consequence of prolonged iron depletion.

Long before haemoglobin falls, iron stores in the body become exhausted. A patient with depleted iron stores but a normal haemoglobin has no anaemia, but they may have profound fatigue, reduced exercise capacity, impaired concentration, and poor quality of life.

The body is compensating, but at a cost. In heart failure particularly, this state of iron deficiency without anaemia is clinically significant and responds well to treatment.

Blood Test	What It Measures	What Low Levels Mean
Ferritin	Iron storage protein, reflects total body iron stores	Low ferritin is the earliest marker of iron depletion, even with normal haemoglobin
Transferrin saturation (TSAT)	Percentage of iron-carrying protein that is actually carrying iron	Below 20% suggests iron is not being delivered to tissues adequately
Haemoglobin (Red blood cell)	Iron is attached to red blood cells. Oxygen requires attachment to the iron on red cells in order to be carried in circulation	Falls late in iron deficiency, a normal result does not exclude iron depletion
Serum iron	Iron circulating in the blood at the time of the test	Variable day-to-day, less reliable than ferritin or TSAT alone

The Evidence for Treating Iron Deficiency in Heart Failure

The clinical trial evidence for intravenous iron in heart failure is now substantial. A large clinical trial (AFFIRM-AHF) showed that intravenous iron, given to iron-deficient patients hospitalised with acute heart failure, significantly reduced the risk of repeat heart failure admissions in the following year.

Patients also reported meaningful improvements in quality of life and their ability to be physically active.

A further large clinical trial (IRONMAN) added weight, showing that regular intravenous iron therapy reduced combined cardiovascular events and hospitalisations over a longer follow-up period. These trials have established correcting iron deficiency as a standard part of heart failure management, not an optional extra.

The AFFIRM-AHF data was genuinely practice-changing. We now routinely check iron studies in every heart failure patient, and treat deficiency proactively, not just when anaemia develops.

— Prof. Peter Barlis, Interventional Cardiologist

How Is Iron Deficiency Treated?

Treatment depends on the severity of deficiency, the underlying cause, and how well the gut can absorb oral iron.

Oral Iron Supplements

For mild iron deficiency without significant gut absorption problems, oral iron supplements, ferrous sulfate, ferrous fumarate, or ferrous gluconate, are a straightforward starting point. They are inexpensive and widely available.

The challenge is tolerability. Oral iron frequently causes nausea, constipation, and abdominal discomfort, particularly in older patients or those on multiple medications. Taking iron with food reduces side effects but also reduces absorption.

Alternate-day dosing has been shown to improve both absorption and tolerability compared to daily dosing, and is now commonly recommended. In patients with heart failure or chronic kidney disease, gut absorption is often impaired enough that oral iron cannot replenish stores adequately, even when tolerated. In these patients, intravenous iron is the more effective route.

Intravenous Iron Infusion

Intravenous iron bypasses the gut entirely, delivering iron directly into the bloodstream where it is immediately available for use. Modern iron preparations specifically designed for infusion, including Ferinject and Monofer, can deliver a large dose in a single session lasting around 15 minutes, making the treatment practical and efficient.

A cannula is placed in a vein in the arm, the infusion runs over the agreed time, and the patient goes home the same day. A small proportion of patients experience mild flushing, fever, hives, muscle ache, joint ache, or a temporary drop in phosphate levels, your team will advise on monitoring if needed. Very rarely, extravasation of iron under the skin can lead to marked discolouration. Serious reactions are rare with modern preparations.

For cardiac patients with significant heart failure and impaired gut absorption, intravenous iron is increasingly the first-line treatment of choice.

What to Expect, Iron Infusion

Preparation

Fasting is not usually required. A cannula is typically placed in the arm on arrival. The infusion generally takes around 15 minutes depending on the preparation used, your team will confirm the details beforehand.

During

Patients are typically monitored throughout. Mild flushing or warmth is common and usually passes quickly. Most people are able to read, use their phone, or rest comfortably during the infusion.

Afterwards

Most patients go home the same day. Many notice an improvement in energy and exercise capacity in the weeks that follow as iron stores are replenished, though timing varies from person to person.

Follow-up

Iron levels are typically rechecked after the infusion, your doctor will advise on timing. In some conditions such as heart failure or chronic kidney disease, repeat infusions may be needed over time.

Should You Ask About Your Iron Levels?

If you are a cardiac patient experiencing unexplained or worsening fatigue, and particularly if you are on long-term aspirin, dual antiplatelet therapy, or anticoagulation, asking your doctor to check a full iron study panel is entirely reasonable.

The test is simple, inexpensive, and the result is directly actionable. Iron studies include ferritin and transferrin saturation (TSAT), both are needed, as ferritin alone can be falsely elevated by inflammation and may miss cases where iron stores appear normal but iron is not actually reaching the body’s tissues properly.

As a general guide, a ferritin below 100 micrograms per litre, or a transferrin saturation below 20%, may suggest iron deficiency is present, though your doctor will interpret these results in the context of your full clinical picture. You do not need to wait until you are anaemic. By that point, iron stores have been empty for some time, and earlier identification tends to lead to better outcomes.

Heart Matters Resource

When in Doubt, Get Checked Out

If you have heart failure, chronic kidney disease, or are on long-term blood-thinning medications and are experiencing significant fatigue, ask your doctor to check your iron studies. It is a simple test and a treatable problem.

Visit our When in Doubt page →

Conclusion

Iron deficiency is common, underdiagnosed, and highly treatable in cardiac patients. Whether it arises from slow blood loss on blood-thinning therapy, from the metabolic demands of heart failure, or from the complex iron handling problems of chronic kidney disease, the end result is the same: depleted stores, profound fatigue, and a quality of life that does not have to be accepted as inevitable.

The evidence that treating iron deficiency in heart failure improves outcomes is now robust. The tools to do it, including intravenous iron infusion, are safe, practical, and increasingly accessible. What is needed is recognition that the problem exists in the first place.

If fatigue is limiting your life and you have not had your iron levels checked recently, that conversation with your doctor is worth having. It may be the most straightforward answer to a problem that has been hiding in plain sight.

SVT (Supraventricular Tachycardia) Explained: Causes and Treatment

April 12, 2026April 12, 2026

SVT causes a sudden, rapid heartbeat, usually harmless but alarming. Knowing your triggers, diagnosis, and treatment options makes it manageable.

How to Lower Blood Pressure Naturally

April 12, 2026April 8, 2026

High blood pressure often has no symptoms, but small changes to lifestyle, supplements, and medication can make a real difference.

An Isolated Inferior Q Wave on Your ECG: Why It’s Usually Nothing to Worry About

April 7, 2026

Key Points

Receiving an ECG report that mentions “possible old heart attack” or “cannot exclude prior infarction” is one of the most anxiety-provoking findings in cardiology, and in an otherwise fit, healthy person with no symptoms, it is almost always a normal variant that requires no treatment.
An ECG records the heart’s electrical activity from 12 different viewpoints around the chest and limbs. A Q wave is simply a small downward dip seen in some of these viewpoints. In certain positions, particularly one called lead III, a Q wave is extremely common in completely normal, healthy hearts.
Automated ECG software flags Q waves as “possible old heart attack” because it cannot apply clinical judgment. A cardiologist reviewing the same ECG in the context of a fit, symptom-free person will almost always reach a very different and reassuring conclusion.
A Q wave that genuinely indicates a previous heart attack must appear in multiple neighbouring viewpoints simultaneously and be accompanied by other supporting changes on the ECG. An isolated Q wave in a single viewpoint, with everything else completely normal, does not meet this standard.
If you have received a report like this and are anxious, that anxiety is entirely understandable. A clinical review with a cardiologist resolves this question quickly and in most cases definitively.

One of the most common referrals I receive, easily once or twice a week, is a fit, healthy, often younger person who has had an ECG for a routine reason and whose report has come back with a phrase like “possible old heart attack,” “Q waves, cannot exclude prior infarction,” or “inferior changes, clinical review advised.”

They arrive in my clinic worried. Some have been unable to sleep. Some have told their families. Some have already started researching heart attack symptoms they have never had. The phrase “old heart attack” in a document about their heart has landed with enormous weight.

In the overwhelming majority of these cases, when I look at the ECG myself, the finding is a small, isolated Q wave in a single ECG viewpoint, a completely normal variant with no clinical significance whatsoever, that tells me nothing concerning about the health of this person’s heart or coronary arteries.

This article exists to explain why, and to give people the information they need before that anxious wait even begins.

Understanding the ECG, a Brief Explanation

What an ECG actually records

An ECG, electrocardiogram, records the electrical activity of the heart using electrodes placed on the chest, arms, and legs. It does not take a picture of the heart. It records the tiny electrical signals that travel through the heart muscle with each beat, triggering the muscle to contract.

Because the electrodes are placed at different positions around the body, the ECG effectively looks at the heart’s electrical activity from 12 different angles, called leads or viewpoints. Each produces its own waveform on the paper trace, and together they give a detailed picture of how electrical signals are moving through the heart. We have a dedicated article on how the ECG works and what it shows on Heart Matters if you would like to understand the test in more depth.

What a Q wave is

Each heartbeat produces a characteristic shape on the ECG trace, a series of peaks and dips. A Q wave is simply a small downward dip at the beginning of the main electrical spike of each beat. In many of the 12 viewpoints, small Q waves are entirely normal, they reflect the normal direction in which the electrical signal travels through the heart at the start of each beat.

In certain viewpoints, particularly one called lead III, which looks at the heart from a specific angle determined by the position of the left arm and left leg electrodes, a Q wave is especially common as a normal finding. It can appear and disappear simply with a change in body position or a deep breath. It is not a sign of damage. It is a reflection of the angle at which that particular viewpoint happens to be looking at the heart.

What Would a Genuine Concern Actually Look Like?

When a heart attack damages an area of heart muscle permanently, that area becomes electrically silent, it no longer generates the normal electrical signals. The ECG viewpoints looking directly at that damaged area will show an abnormal Q wave as a result, deeper, broader, and more prominent than a normal variant Q wave.

But, and this is the critical point, a heart attack affecting any meaningful area of muscle will show these changes across multiple neighbouring ECG viewpoints simultaneously, not in just one. It will also typically be accompanied by other supporting changes in the same viewpoints, changes in the shape of the waveform, and changes in the pattern of recovery between beats.

An isolated Q wave appearing in just one viewpoint, with every other viewpoint completely normal and no supporting changes anywhere on the trace, does not fit this picture at all. It is simply not how genuine heart attack scarring presents on an ECG.

Why the Software Gets It Wrong

Modern ECG machines include automated interpretation software that analyses the trace and generates a written report. This software is useful, it can reliably identify certain patterns and flag them for clinical review. But it has an important limitation: it cannot think clinically.

When the software sees a Q wave in a particular viewpoint, it flags “possible old heart attack, clinical correlation recommended.” It cannot consider that the person is 32 years old and plays sport twice a week. It cannot consider that the Q wave is tiny and only visible in one viewpoint. It cannot consider that the person has never had any cardiac symptom in their life. It simply matches the pattern and generates the flag.

That flag is not a diagnosis. It is a prompt for a clinician to look at the full picture, and when a clinician does, the picture is almost always entirely reassuring.

In most of these referrals, one look at the ECG in the context of the patient in front of me resolves the question immediately. The report did its job. The clinical review does the rest.

— Prof. Peter Barlis, Interventional Cardiologist

Normal Variant vs Genuine Concern, Plain Language Guide

Feature	Almost certainly a normal variant	Worth investigating further
How many viewpoints show the Q wave	Only one viewpoint on the entire ECG	Multiple neighbouring viewpoints showing the same change
The rest of the ECG	Completely normal in every other respect	Other changes present in the same viewpoints
The person’s history	No cardiac symptoms ever, no risk factors, fit and active	History of chest pain, breathlessness, or cardiovascular risk factors
Does it change with breathing	Q wave reduces or disappears with a deep breath	Persistent regardless of position or breathing
Why the ECG was done	Routine, pre-employment, or incidental finding	ECG done because of symptoms or known cardiac history
Echocardiogram result	Normal heart structure and function throughout	Abnormal muscle movement in the area the Q wave viewpoints correspond to

What Investigation Is Actually Needed?

A clinical review, not a cascade of tests

The appropriate response to a report like this in an otherwise healthy person is a clinical review with a cardiologist, not an immediate referral for a stress test, a CT scan of the coronary arteries, or a coronary angiogram. A cardiologist looking at the ECG alongside your history and examination can in most cases answer the question definitively without any further testing at all.

If any uncertainty remains after that review, perhaps because there are some cardiovascular risk factors present, or because the ECG changes are borderline, an echocardiogram is the most efficient next step. This is an ultrasound of the heart that shows how the heart muscle is moving. If the muscle in the area corresponding to the Q wave viewpoint is moving completely normally, which it almost always is in these situations, that is powerful additional reassurance that no significant heart attack has occurred.

What you do not need

A fit, active, symptom-free person with no cardiovascular risk factors whose ECG shows an isolated Q wave in a single viewpoint, with everything else normal, does not need urgent investigation. They do not need to stop exercising while they wait for a result. They need a clinical review that puts the automated report in its proper context, and in most cases, that conversation is the only investigation needed.

If you have received a report like this, what to hold onto

An automated ECG report is generated by software, not a cardiologist. Its job is to flag things for clinical review, not to make diagnoses.
A Q wave appearing in just one ECG viewpoint, with everything else completely normal, is almost always a normal finding in an otherwise healthy heart.
A Q wave pattern that genuinely indicates a previous heart attack appears across multiple neighbouring viewpoints simultaneously, not in isolation.
A cardiologist reviewing your ECG alongside your history will almost always be able to give you a clear and reassuring answer, often without any further testing.
An echocardiogram, an ultrasound of the heart, is the most direct additional reassurance if any uncertainty remains after clinical review.

Heart Matters Resource

When in Doubt, Get Checked Out

If your ECG report mentions Q waves or a possible old heart attack and you are anxious about it, a cardiology review will answer the question efficiently and in most cases very reassuringly. Do not sit with that anxiety without getting it properly assessed.

Read: When in Doubt, Get Checked Out →

Conclusion

The automated ECG report that says “possible old heart attack” is one of the most anxiety-generating phrases in cardiology, and in a fit, healthy, symptom-free person it is almost always an over-call by software that cannot apply clinical judgment. The Q wave it has flagged is real. The interpretation it has placed on that finding is almost certainly wrong in this context.

A Q wave appearing in just one ECG viewpoint, with no other changes anywhere on the trace, in a person who has never had cardiac symptoms and has no significant risk factors, is a normal finding. It does not mean your heart is damaged. It does not mean you have had a heart attack. And it does not mean you need urgent investigation.

What it means is that you need a cardiologist to look at your ECG and your history together, and give you the reassurance that the software, by its nature, simply cannot provide.

A Living Legend of Interventional Cardiology: Professor Patrick Serruys

April 7, 2026April 6, 2026

heartmatters.com 2026 04 06T204658.338 1

Key Points

Professor Patrick Serruys is one of the most influential figures in the history of interventional cardiology, with over 3,500 peer-reviewed publications and 250,000 citations.
He introduced balloon angioplasty to the Netherlands in 1980 and performed the country’s first coronary stent implantation in 1986.
He helped pioneer drug-eluting stents, now the global standard of care, implanted in millions of patients every year.
In 2004, he performed the first percutaneous aortic valve replacement in the Netherlands, a procedure now known as TAVI.
He remains scientifically active today, continuing to shape the future of cardiovascular medicine.

Last week, I had the honour of presenting a lifetime achievement award to a man who shaped not only my career, but the entire field of interventional cardiology. Professor Patrick Serruys visited Sydney, and standing in front of him with that award in my hands, I found myself thinking about the extraordinary distance modern heart medicine has travelled, and how much of that journey he personally led.

Patrick was my PhD supervisor. He wrote the foreword to my book on heart stents. We continue to collaborate to this day. But this article is not really about my connection to him, it is about what his work means for patients. Because if you or someone you love has ever had a coronary stent, a drug-eluting stent, or a catheter-based heart valve procedure, there is a very real chance that the treatment you received exists in its current form because of Professor Serruys.

Where It All Began

Patrick Serruys published his first scientific paper in the British Heart Journal in 1978. He was working at the Thoraxcenter in Rotterdam, then a young institution that would become one of the most important centres of cardiovascular innovation in the world. From the very beginning, he was drawn to a question that would define his career: could blocked heart arteries be treated without open-heart surgery?

At the time, the answer was far from obvious. Coronary artery bypass surgery was the standard of care. The idea that a cardiologist could thread a thin catheter through the blood vessels, navigate to a blocked artery in the heart, and open it from the inside, without a single incision on the chest, was genuinely radical.

In September 1980, Professor Serruys introduced balloon angioplasty to Rotterdam. A small balloon on the tip of a catheter, inflated inside the narrowed artery to compress the blockage and restore blood flow. It worked. But it had a significant problem, the artery often narrowed again within months, a process called restenosis. For more than a decade, he led thirteen clinical trials attempting to solve this problem with medications. The results were disappointing.

The history of medicine is full of researchers who, faced with repeated setbacks, simply kept going. What distinguishes Professor Serruys is that each disappointment redirected his curiosity rather than diminishing it. The solution to restenosis, it turned out, was not a drug, it was a device.

The Stent That Changed Everything

In 1986, Professor Serruys performed the first coronary stent implantation in the Netherlands, just months after the very first procedures anywhere in the world. A coronary stent is a tiny mesh scaffold, deployed inside the artery to hold it open after balloon angioplasty. It was a transformative development. Restenosis rates fell. Patients did better.

But the stent itself still caused some degree of restenosis in a proportion of patients, because the metal triggered a healing response from the artery wall that could cause re-narrowing over time. The next challenge was clear: could the stent itself deliver medication directly to the artery wall to prevent this response?

By the late 1990s, working with colleagues in Rotterdam and São Paulo, Professor Serruys helped pioneer the first drug-eluting stents stents coated with medication that releases slowly into the surrounding tissue, dramatically reducing restenosis. In 2000, during one of cardiology’s most prestigious lectures, he predicted this technology would spread worldwide. It did. Drug-eluting stents are now the global standard of care for coronary intervention, implanted in millions of patients every year.

In 1994, he led the first randomised controlled trial directly comparing stenting with balloon angioplasty alone, published in the New England Journal of Medicine, which contributed to regulatory approval of coronary stents by the United States FDA that same year. If you want to understand the evidence behind the stent in your own chest, you can read more on our Coronary Artery Disease page.

Beyond the Stent

Even as stenting transformed interventional cardiology, Professor Serruys was already thinking about its limitations. A permanent metallic scaffold left forever inside a coronary artery troubled him. What if the scaffold could dissolve once its job was done, leaving the artery free and natural?

In 2006, he introduced fully biodegradable coronary scaffolds made from polylactic acid, the same material used in dissolvable surgical sutures, that provided the structural support of a stent during the critical healing period, then gradually disappeared over two to three years. The concept and early results were published in The Lancet and the New England Journal of Medicine. This remains an active and evolving area of research.

His curiosity never stayed confined to coronary arteries. In 2004, together with the pioneering French cardiologist Alain Cribier, he performed the first percutaneous aortic valve replacement in the Netherlands threading an artificial heart valve through the blood vessels and implanting it inside the diseased native valve, without open-heart surgery. This procedure, now known as TAVI, has since transformed the treatment of aortic stenosis and is now offered to tens of thousands of patients worldwide who previously had no good surgical option.

Professor Patrick Serruys presenting at Sydney Intervention 2026 — Professor Serruys presenting at Sydney Intervention 2026, his lecture on the future of coronary revascularisation included fifteen predictions for the field, published in the European Heart Journal.

The Scale of a Career

Numbers can feel abstract, but in this case they help convey something genuinely difficult to communicate in words. Professor Serruys has published more than 3,500 peer-reviewed scientific papers. His work has been cited more than 250,000 times by other researchers, placing him among the most cited medical scientists on the planet.

He has trained more than 400 interventional cardiologists and supervised more than 100 PhD candidates many of whom are now leading figures in the field in their own right. I am proud to count myself among them.

He is the author or co-author of 43 books and monographs, including three editions of the European Society of Cardiology’s flagship textbook of cardiovascular medicine. He holds an honorary doctorate in engineering from the University of Melbourne, a recognition that his contributions straddled the boundary between clinical medicine and biomedical engineering.

At the time of writing, he remains scientifically active at the University of Galway, where he established a research centre focused on advanced imaging and core laboratory science after his 36-year career at Erasmus University in Rotterdam. He cycles to the laboratory every day.

Professor Patrick Serruys and Prof. Peter Barlis at the University of Melbourne honorary doctorate ceremony 2016 — Professor Serruys receiving his honorary doctorate in engineering from the University of Melbourne in 2016, pictured with Prof. Peter Barlis.

What This Means for Patients

I am sometimes asked by patients why any of this history matters to them. The answer is simple. Every time a cardiologist threads a stent into a blocked coronary artery, a procedure that takes less than an hour, requires no general anaesthetic, and sends most patients home the same day, they are building on decades of work by researchers like Professor Serruys who refused to accept that open-heart surgery was the only answer.

The treatments we now consider routine were once considered impossible. They exist because of people who asked difficult questions, ran rigorous trials, published honest results, including failures, and kept pushing. Understanding that journey helps patients engage more confidently with their own care.

New Release 2026

Heart Stents: What You Need to Know

A comprehensive guide by Professor Peter Barlis, with a foreword by Professor Patrick Serruys. Published by Wiley.

Buy on Amazon →

Conclusion

Presenting that lifetime achievement award to Patrick last week, in Sydney, surrounded by colleagues whose careers he has shaped, was one of the genuine privileges of my professional life. The field of interventional cardiology owes him an enormous debt.

And so, indirectly, do the millions of patients whose lives have been changed by the treatments he helped bring into existence. If you have ever had a stent placed, a valve replaced without open-heart surgery, or benefited from any of the imaging technologies now used in the catheterisation laboratory, there is a very good chance that Professor Serruys played a role in making that possible.

That is a legacy worth celebrating, not just within cardiology, but for every patient who has sat in a recovery room, gone home the next morning, and returned to their life.

Professor Patrick Serruys receives a standing ovation at Sydney Intervention 2026 — Sydney Intervention 2026, a room full of cardiologists rises as Professor Serruys receives the lifetime achievement award.

How Atrial Fibrillation Is Treated: From Lifestyle to Ablation

April 21, 2026March 27, 2026

Managing atrial fibrillation involves more than just medication, it is a personalised strategy covering lifestyle, rate control, rhythm control, and stroke prevention.

Heart Health in Asian Populations

April 9, 2026March 26, 2026

Key Points

People of South Asian background, with ancestry from India, Pakistan, Bangladesh, Sri Lanka, and Nepal, tend to develop heart disease earlier than Western populations, often at lower body weights. The good news is that this risk is very well understood and very actionable with the right awareness and early assessment.
People of East Asian background, with ancestry from China, Japan, Korea, and Southeast Asia, have a different but equally important cardiovascular profile, with higher rates of stroke and blood pressure-driven heart disease. Again, this is a risk profile that responds very well to early identification and management.
Standard cardiovascular risk calculators used by doctors were developed mainly in Western populations and may underestimate risk in South and East Asian individuals, which is why proactively raising your background in a cardiovascular risk conversation is so valuable.
Diabetes develops at lower body weights in both South and East Asian populations than in Western populations, making blood sugar assessment important even in people who appear slim by standard measures.
Early engagement with your healthcare team, even without symptoms, is the single most effective step people from these communities can take. The earlier the conversation, the more options are available.

If you are of South Asian or East Asian background, this article is written specifically for you, and it carries a message that is ultimately optimistic, not alarming.

Yes, the evidence shows that people from these communities face cardiovascular risks that are not fully captured by standard medical tools designed for Western populations. But the reason to know this is not to worry, it is to act. Because the cardiovascular risks that affect South and East Asian populations are well understood, largely preventable, and highly responsive to early intervention.

The most powerful thing you can do with the information in this article is use it to start a more specific and more informed conversation with your doctor. That conversation, had early, before symptoms develop, is where the difference is made.

Why Standard Risk Tools Sometimes Miss the Picture

Doctors use scoring tools and calculators to estimate a patient’s risk of having a heart attack or stroke over the next ten years. These tools consider age, blood pressure, cholesterol levels, smoking history, and family history, and they are genuinely useful. But they were developed and tested primarily using data from white Western European and North American populations.

For people of South Asian or East Asian background, these tools can underestimate risk, sometimes significantly. The body weight thresholds, cholesterol ranges, and blood pressure cut-offs that signal concern in a Western patient do not always apply in the same way. The result is that some people from these communities are told their risk is low when a more targeted assessment would identify important factors worth addressing.

This is not a failure of medicine, it is a gap that is now well recognised and being actively addressed in cardiovascular research. Knowing about it puts you in a position to ask the right questions.

South Asian Communities, What the Evidence Shows

Who this section applies to

South Asian refers to people with family roots in India, Pakistan, Bangladesh, Sri Lanka, Nepal, and Bhutan. This is one of the largest communities in Australia, the United States, the United Kingdom, and Canada, and one that carries a cardiovascular risk profile that deserves specific attention and specific action.

Heart disease tends to arrive earlier

Coronary artery disease, the narrowing of the arteries that supply the heart with blood, tends to develop earlier in South Asian individuals than in Western populations. This is not inevitable, and it is not a reason for fatalism. It is a reason for earlier, more proactive engagement with cardiovascular risk assessment, because identifying and managing risk factors in your thirties or forties is far more effective than waiting for symptoms to appear.

The disease also tends to affect the smaller coronary arteries, which are harder to see on some investigations and more diffuse in its distribution. This is another reason why a thorough assessment, rather than a single test, gives the most complete picture.

Act Early

For people of South Asian background, starting cardiovascular risk conversations with your doctor in your thirties rather than waiting for symptoms is one of the most effective things you can do for your long-term heart health. Early assessment means early action, and early action produces the best outcomes.

Body weight, why standard measures can be misleading

The standard BMI, body mass index, thresholds used in Western medicine define overweight as a BMI above 25 and obese above 30. These thresholds were developed using data from Western populations and do not translate directly to South Asian individuals.

South Asian bodies tend to carry more fat around the abdomen, even at lower overall body weights, and this abdominal fat pattern is more strongly linked to metabolic problems like insulin resistance, high blood sugar, and abnormal cholesterol than fat carried elsewhere. As a result, a South Asian person with a BMI of 23 or 24, technically “normal weight” by standard measures, may already have a metabolic profile that warrants attention and management.

Waist circumference, the measurement around the middle, is a more useful indicator of this risk than BMI alone. If you are of South Asian background, asking your doctor to measure your waist circumference alongside your weight gives a more complete picture of your cardiometabolic health.

Diabetes, why it develops earlier and at lower weights

Type 2 diabetes, a condition where the body does not manage blood sugar properly, is two to four times more common in South Asian populations than in white Western populations, and it tends to develop at younger ages and lower body weights. This matters enormously for cardiovascular health because diabetes significantly amplifies the risk of heart disease and stroke when it is present.

The practical implication is that a blood sugar test, specifically an HbA1c, which gives a three-month average of blood sugar control, is worth requesting even if you are not overweight and have no obvious symptoms of diabetes. Identifying pre-diabetes or early diabetes early gives the best chance of reversing it before it affects the heart.

Lp(a), an inherited risk factor worth knowing about

Lipoprotein(a), usually written as Lp(a) and pronounced “L-P-little-a”, is an inherited particle in the blood that raises cardiovascular risk. It is not affected by diet, exercise, or standard cholesterol-lowering medications, and it is carried in elevated amounts by a higher proportion of South Asian individuals than most other populations.

Most people have never had their Lp(a) measured, because it is not part of standard cholesterol testing. But it is a simple blood test, needs only to be done once in a lifetime, and identifies an important risk factor that completely changes the management conversation when it is elevated. We have a dedicated article on Lp(a) and what it means for your heart on Heart Matters. If you are of South Asian background, particularly with a family history of early heart disease, asking your doctor about Lp(a) is one of the most valuable things you can do at your next appointment.

As someone of South Asian background myself, this is not an abstract clinical observation, it is something I see in my own extended family and community. The patients who arrive in my operating theatre with advanced coronary disease in their forties are often people whose risk was underestimated for years because the standard tools were not built with them in mind. Earlier conversations change outcomes. I have seen it.

— Prof. Jai Raman, Cardiothoracic Surgeon

East Asian Communities, What the Evidence Shows

Who this section applies to

East Asian refers to people with family roots in China, Japan, Korea, Taiwan, Hong Kong, and Mongolia. Southeast Asian encompasses Vietnam, Thailand, the Philippines, Indonesia, Malaysia, Cambodia, and neighbouring countries. While these are richly diverse populations with very different cultural and dietary traditions, they share some important cardiovascular patterns that are worth understanding.

Stroke, the priority risk to manage

East Asian populations generally have lower rates of coronary artery disease, blocked heart arteries, compared to South Asian or Western populations. This is genuinely positive and reflects the protective effects of traditional dietary patterns and historically lower rates of obesity in these communities.

However, stroke rates are higher, and this is the cardiovascular priority for East Asian populations. A stroke occurs when blood supply to part of the brain is interrupted, either by a blocked artery or a burst blood vessel. Both types are more common in East Asian populations than in Western ones, and both are strongly driven by high blood pressure, which is the most important cardiovascular risk factor to manage in these communities.

Blood pressure and salt, a particularly important connection

High blood pressure, or hypertension, is the dominant cardiovascular risk factor in East Asian populations, and it responds particularly strongly to dietary salt intake. Many traditional East Asian cuisines are naturally high in sodium, from soy sauce, fish sauce, miso, preserved vegetables, and processed foods, and this dietary pattern can contribute meaningfully to blood pressure elevation over time.

The good news is that this is one of the most modifiable risk factors available. Reducing dietary sodium, alongside medication where needed, produces very meaningful reductions in blood pressure and stroke risk. Having your blood pressure checked regularly, and monitoring it at home with a home blood pressure device, is one of the highest-value health habits for anyone of East Asian background. We have a dedicated article on monitoring blood pressure at home on Heart Matters.

Atrial fibrillation, a specific conversation worth having

Atrial fibrillation, or AF, is a common heart rhythm condition where the upper chambers of the heart beat irregularly rather than in a coordinated rhythm. When AF is present, blood can pool in the heart and form clots, which can travel to the brain and cause a stroke. We have a dedicated article on AF and stroke risk on Heart Matters.

In East Asian populations, the stroke risk associated with AF appears to be somewhat higher than in Western populations, which means the decision about whether to use blood-thinning medication to protect against stroke is particularly important. If you have been diagnosed with AF and are of East Asian background, having an explicit conversation with your cardiologist about your stroke risk and the best approach to managing it is very worthwhile.

Sleep apnoea at lower body weights

Obstructive sleep apnoea, a condition where breathing repeatedly stops and starts during sleep, is a significant but under-recognised cardiovascular risk factor. It is associated with high blood pressure, atrial fibrillation, and heart failure. Most people are aware that it is more common in people who are overweight, but in East and Southeast Asian populations, sleep apnoea develops at significantly lower body weights than in Western populations, due to differences in facial bone structure that affect the size of the upper airway.

This means that a lean East Asian person with heavy snoring, morning headaches, or unrefreshing sleep should be assessed for sleep apnoea regardless of their weight. We cover this in detail in our dedicated article on obstructive sleep apnoea and the heart.

Alcohol, an important note for East Asian individuals

Approximately one in three people of East Asian background carries a genetic variation that affects how the body processes alcohol. When alcohol is consumed, the body normally breaks it down through a series of steps. In people with this genetic variation, one of those steps does not work properly, causing a build-up of a toxic substance called acetaldehyde. This produces the characteristic facial flushing, redness of the face and neck, that many East Asian people experience after even small amounts of alcohol.

This flushing is not merely a cosmetic reaction. The acetaldehyde that builds up is a direct cardiovascular toxin and is also linked to an increased risk of certain cancers. For people of East Asian background who experience this flushing response, there is a particularly strong cardiovascular reason to keep alcohol consumption to a minimum. We discuss this further in our dedicated article on alcohol and the heart.

The Positive Picture, What Early Action Achieves

Everything described in this article is actionable. Every risk factor mentioned, blood pressure, blood sugar, Lp(a), sleep apnoea, cholesterol, dietary sodium, alcohol, can be identified with simple tests, and most can be meaningfully reduced with a combination of lifestyle changes and, where needed, medication.

The cardiovascular outcomes for South and East Asian patients who are identified early and managed proactively are excellent. The gap in outcomes between these populations and Western populations is not biological destiny, it is largely a consequence of later presentation and less targeted risk assessment. Change those two things, and the outcomes change with them.

The most important step is the first one: a conversation with your doctor that explicitly addresses your background and what it means for your cardiovascular risk assessment.

Background	Priority areas to discuss with your doctor	Key tests worth asking about
South Asian	Earlier cardiovascular risk assessment, diabetes screening at lower BMI, family history of early heart disease, abdominal weight distribution	Lp(a) blood test, HbA1c, waist circumference, full lipid profile, blood pressure
East Asian	Blood pressure control and home monitoring, dietary sodium, stroke risk if AF is present, sleep apnoea assessment, alcohol and the ALDH2 flushing response	Home blood pressure readings, HbA1c, sleep study if snoring or unrefreshing sleep, ECG if palpitations
Southeast Asian	Overlapping features from both groups above; rheumatic heart disease history if from an endemic region	Individualised based on specific background, discuss with your doctor what applies most to you

The patients I worry least about are the ones who come to see me early, before symptoms, before a crisis, and say “I know my background puts me at higher risk, so I want to understand where I stand.” That conversation, had in your thirties or forties, gives us every opportunity to protect your heart for decades to come.

— Prof. Peter Barlis, Interventional Cardiologist

A Note on Acculturation, Second and Third Generations

One pattern worth understanding is what happens as South and East Asian families become more established in Western countries across generations. First-generation immigrants often maintain the dietary patterns of their home country, which, particularly for East Asian families, can be quite protective. Second and third generations frequently adopt more Western eating habits, more processed food, more refined carbohydrate, less of the traditional plant-based and fermented foods, while sometimes losing awareness of the specific cardiovascular risks their background carries.

If you are a second or third-generation Australian, American, or British person of South or East Asian descent, the cardiovascular risk profile of your ethnic background applies to you just as much as it does to a first-generation immigrant. It is worth knowing about, and worth discussing with your doctor.

Questions to raise at your next appointment

Does my South Asian or East Asian background affect my cardiovascular risk, and does the standard risk calculator my practice uses account for this?
Should I have my Lp(a) measured? I understand it is elevated more commonly in people of South Asian background.
Can we check my waist circumference and HbA1c alongside my standard blood tests, even though I am not overweight?
I have AF, does my background affect my stroke risk or the best approach to anticoagulation for me?
I snore and wake feeling unrefreshed, should I be assessed for sleep apnoea regardless of my weight?

Free Download, Heart Matters

Our Heart Health Risk Factor Checklist covers 12 cardiovascular risk categories, a useful tool to complete before any appointment, to ensure the full picture is discussed and nothing important is overlooked.

Download the Risk Factor Checklist →

Heart Matters Resource

When in Doubt, Get Checked Out

If you are of South Asian or East Asian background and have not had a cardiovascular risk assessment that explicitly accounts for your ethnic background, that conversation with your doctor is one of the most valuable you can have. Start it today.

Read: When in Doubt, Get Checked Out →

Conclusion

The cardiovascular risks that affect South and East Asian communities are real, well understood, and highly manageable when identified early. The standard medical tools that doctors use every day were not built with your specific background in mind, which means you may need to be the one who brings this conversation to your appointment.

That is not a burden, it is an opportunity. The person who walks into their doctor’s office armed with this awareness, asks the right questions, and gets the right assessment is the person who gives themselves the best possible chance of a long and healthy life.

Your background is not your destiny. It is information, and information, acted on early, is one of the most powerful tools in cardiovascular medicine.

Understanding Ventricular Tachycardia: and Why Treatment Works

April 7, 2026March 10, 2026

Ventricular tachycardia is a fast heart rhythm originating in the lower chambers of the heart. With the treatments available today, most people do very well.

Conditions

Does a Coffee a Day Keep AF at Bay?

Iron Deficiency and the Heart

SVT (Supraventricular Tachycardia) Explained: Causes and Treatment

How to Lower Blood Pressure Naturally

An Isolated Inferior Q Wave on Your ECG: Why It’s Usually Nothing to Worry About

A Living Legend of Interventional Cardiology: Professor Patrick Serruys

How Atrial Fibrillation Is Treated: From Lifestyle to Ablation

Heart Health in Asian Populations

Understanding Ventricular Tachycardia: and Why Treatment Works

Obstructive Sleep Apnoea and the Heart: Why It’s So Often Missed

When a Slow Heart Rate Is Not Normal: Understanding Bradycardia

POTS: Understanding Postural Orthostatic Tachycardia Syndrome

SVT: A Nasal Spray That Can Stop an Episode at Home

Heart Health During Pregnancy: What You Need to Know

New in Conditions, delivered weekly

Heart Attack vs Cardiac Arrest: What is the Difference?

Women’s Heart Health: Why It’s Different

Rheumatic Heart Disease: A Preventable Condition Affecting Millions

What is the DECAF trial?

Why might coffee help rather than hurt?

What are the limitations of this trial?

What does this mean for you?

Conclusion

More from Heart Matters

References

Key Points

Iron Deficiency and the Heart, Why Are Cardiac Patients at Risk?

Blood-Thinning Medications and Slow Blood Loss

Heart Failure

Chronic Kidney Disease

Iron Deficiency Without Anaemia, Why This Matters

The Evidence for Treating Iron Deficiency in Heart Failure

How Is Iron Deficiency Treated?

Oral Iron Supplements

Intravenous Iron Infusion

Should You Ask About Your Iron Levels?

When in Doubt, Get Checked Out

Conclusion

More from Heart Matters

Understanding the ECG, a Brief Explanation

What an ECG actually records

What a Q wave is

What Would a Genuine Concern Actually Look Like?

Why the Software Gets It Wrong

Normal Variant vs Genuine Concern, Plain Language Guide

What Investigation Is Actually Needed?

A clinical review, not a cascade of tests

What you do not need

When in Doubt, Get Checked Out

Conclusion

More from Heart Matters

Where It All Began

The Stent That Changed Everything

Beyond the Stent

The Scale of a Career

What This Means for Patients

Conclusion

Why Standard Risk Tools Sometimes Miss the Picture

South Asian Communities, What the Evidence Shows

Who this section applies to

Heart disease tends to arrive earlier

Body weight, why standard measures can be misleading

Diabetes, why it develops earlier and at lower weights

Lp(a), an inherited risk factor worth knowing about

East Asian Communities, What the Evidence Shows

Who this section applies to

Stroke, the priority risk to manage

Blood pressure and salt, a particularly important connection

Atrial fibrillation, a specific conversation worth having

Sleep apnoea at lower body weights

Alcohol, an important note for East Asian individuals

The Positive Picture, What Early Action Achieves

A Note on Acculturation, Second and Third Generations

When in Doubt, Get Checked Out

Conclusion

More from Heart Matters

Stay Informed